Compare Sincere Co., Ltd. (Japan) with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 8.80%
- The company has been able to generate a Return on Equity (avg) of 8.80% signifying low profitability per unit of shareholders funds
2
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 8.80%
3
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 8.80%
4
The company has declared Negative results for the last 3 consecutive quarters
5
With ROE of 9.31%, it has a very attractive valuation with a 1.15 Price to Book Value
6
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 3,191 Million (Micro Cap)
12.00
NA
0.00%
0.05
9.31%
1.15
Revenue and Profits:
Net Sales:
1,935 Million
(Quarterly Results - Mar 2026)
Net Profit:
68 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.95%
0%
7.95%
6 Months
-3.65%
0%
-3.65%
1 Year
-15.18%
0%
-15.18%
2 Years
26.67%
0%
26.67%
3 Years
-19.08%
0%
-19.08%
4 Years
13.64%
0%
13.64%
5 Years
-16.52%
0%
-16.52%
Sincere Co., Ltd. (Japan) for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.05%
EBIT Growth (5y)
19.64%
EBIT to Interest (avg)
32.50
Debt to EBITDA (avg)
0.65
Net Debt to Equity (avg)
0.16
Sales to Capital Employed (avg)
1.43
Tax Ratio
41.59%
Dividend Payout Ratio
41.75%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.77%
ROE (avg)
8.80%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.15
EV to EBIT
6.42
EV to EBITDA
5.53
EV to Capital Employed
1.14
EV to Sales
0.42
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
17.81%
ROE (Latest)
9.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
1,935.40
2,036.80
-4.98%
Operating Profit (PBDIT) excl Other Income
163.60
150.40
8.78%
Interest
6.50
5.70
14.04%
Exceptional Items
1.90
-62.40
103.04%
Consolidate Net Profit
68.50
17.20
298.26%
Operating Profit Margin (Excl OI)
74.00%
63.60%
1.04%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -4.98% vs 9.05% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 298.26% vs -77.75% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
7,456.10
6,539.40
14.02%
Operating Profit (PBDIT) excl Other Income
619.40
564.60
9.71%
Interest
22.90
16.90
35.50%
Exceptional Items
-66.50
2.80
-2,475.00%
Consolidate Net Profit
264.30
309.10
-14.49%
Operating Profit Margin (Excl OI)
70.30%
74.10%
-0.38%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.02% vs 9.69% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -14.49% vs 4.60% in Dec 2024
About Sincere Co., Ltd. (Japan) 
Sincere Co., Ltd. (Japan)
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






